Log in
Enquire now
Gedea Biotech

Gedea Biotech

Developer of an antibiotic-free treatment intended to treat and prevent vaginal bacterial and fungal infections. The company's treatment offers natural substances that restore the vaginal pH level as well as provide physical barrier protection and inhibit biofilm formation, enabling women to have an antibiotic-free, safe and effective treatment.

OverviewStructured DataIssuesContributors

Contents

gedeabiotech.com/en
gedeabiotech.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Drug discovery
Drug discovery
0
0
Health technology
Health technology
Biotechnology
Biotechnology
0
Biology
Biology
Technology
Technology
Location
Lund
Lund
0
CEO
Pitchbook URL
pitchbook.com/profiles...222801-22
Legal Name
Gedea Biotech AB0
Number of Employees (Ranges)
1 – 10
Email Address
Phone Number
Number of Employees
30
Full Address
Medicon Village Scheeletorget 1 223 81 Lund Swede0
Investors
Lourens Verweij
Lourens Verweij
Additio Investment Group
Additio Investment Group
Founded Date
2015
0
Total Funding Amount (USD)
1,300,000
Latest Funding Round Date
May 24, 2023
Latest Funding Type
Seed
Seed
Patents Assigned (Count)
1
Country
Sweden
Sweden
0
Headquarters
Lund
Lund

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
1,300,000
Public/Private
Private0
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Gedea Biotech

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.